Topical SCD-153, A 4-Methyl Itaconate Prodrug, For The Treatment Of Alopecia Areata

    December 2022 in “ PNAS nexus ”
    Jerry Tsai, Sadakatali S. Gori, Jesse Alt, Sandhya Tiwari, Jitesh Iyer, Rashmi Talwar, Denish Hinsu, Kailash Ahirwar, Swayam Mohanty, Chintan Khunt, Brijesh Sutariya, Kaushal Jani, Venkatesha Venkatasubbaiah, Ashok R. Patel, Jasmin Meghapara, K. Joshi, Rajanikanta Sahu, Ritu Vijay, Prashant B. Nigade, Ravi S. Talluri, Kadiyala V S N Murty, Kiritkumar Joshi, Vikram Ramanathan, Ang Li, Nasif Islam, Ivan Šnajdr, Pavel Majer, Rana Rais, Barbara S. Slusher, Luis A. Garza
    From the encyclopedia
    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Tofacitinib →

    a JAK inhibitor for alopecia areata and other autoimmune conditions

    Image
    Studysummary In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    SCD-153, a prodrug of 4-methyl itaconate (4-MI), was developed to treat alopecia areata by enhancing skin and cell penetration. In C57BL/6 mice, topical SCD-153 converted to 4-MI upon skin penetration and showed low systemic absorption. It significantly reduced inflammatory markers in human epidermal keratinocytes and induced significant hair growth in mice, outperforming vehicle, less cell-permeable itaconate analogues, and the JAK inhibitor tofacitinib. These findings suggest that SCD-153 is a promising topical treatment for alopecia areata.
    Discuss this study in the Community →

    Research cited in this study

    21 / 21 results